BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36572102)

  • 41. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
    Lloyd AJ; Kerr C; Penton J; Knerer G
    Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
    Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
    J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
    [No Abstract]   [Full Text] [Related]  

  • 43. Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale.
    Bulamu NB; Chen G; McGrane E; Cock C; Young GP; Symonds EL
    Cancer Causes Control; 2024 Feb; 35(2):347-357. PubMed ID: 37747615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A structured review of health utility measures and elicitation in advanced/metastatic breast cancer.
    Hao Y; Wolfram V; Cook J
    Clinicoecon Outcomes Res; 2016; 8():293-303. PubMed ID: 27382319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study.
    Ndosi M; Alcacer-Pitarch B; Allanore Y; Del Galdo F; Frerix M; García-Díaz S; Hesselstrand R; Kendall C; Matucci-Cerinic M; Mueller-Ladner U; Sandqvist G; Torrente-Segarra V; Schmeiser T; Sierakowska M; Sierakowska J; Sierakowski S; Redmond A
    Ann Rheum Dis; 2018 Jul; 77(7):1032-1038. PubMed ID: 29463517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.
    Norman R; Viney R; Aaronson NK; Brazier JE; Cella D; Costa DS; Fayers PM; Kemmler G; Peacock S; Pickard AS; Rowen D; Street DJ; Velikova G; Young TA; King MT
    Qual Life Res; 2016 Mar; 25(3):637-49. PubMed ID: 26342928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer.
    Bulamu NB; Chen G; Ratcliffe J; Schloite A; Bright T; Watson DI
    World J Surg; 2019 Jun; 43(6):1554-1562. PubMed ID: 30719557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
    Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
    J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
    [No Abstract]   [Full Text] [Related]  

  • 51. Health-related quality of life and its predictors among patients with breast cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
    Sibhat SG; Fenta TG; Sander B; Gebretekle GB
    Health Qual Life Outcomes; 2019 Nov; 17(1):165. PubMed ID: 31690327
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment.
    Pilz MJ; Aaronson NK; Arraras JI; Caocci G; Efficace F; Groenvold M; Holzner B; van Leeuwen M; Loth FLC; Petersen MA; Ramage J; Tomaszewski KA; Young T; Giesinger JM
    J Palliat Med; 2021 Mar; 24(3):397-404. PubMed ID: 32835601
    [No Abstract]   [Full Text] [Related]  

  • 53. International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer.
    Petersen MA; Aaronson NK; Conroy T; Costantini A; Giesinger JM; Hammerlid E; Holzner B; Johnson CD; Kieffer JM; van Leeuwen M; Nolte S; Ramage JK; Tomaszewski KA; Waldmann A; Young T; Zotti P; Groenvold M;
    Qual Life Res; 2020 May; 29(5):1405-1417. PubMed ID: 31955374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The EORTC QLQ-OH17: a supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients.
    Hjermstad MJ; Bergenmar M; Fisher SE; Montel S; Nicolatou-Galitis O; Raber-Durlacher J; Singer S; Verdonck-de Leeuw I; Weis J; Yarom N; Herlofson BB
    Eur J Cancer; 2012 Sep; 48(14):2203-11. PubMed ID: 22572480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population-based reference values for the European Organization for Research and Treatment of Cancer Head and Neck module.
    Hammerlid E; Adnan A; Silander E
    Head Neck; 2017 Oct; 39(10):2036-2047. PubMed ID: 28708279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity.
    Juul T; Petersen MA; Holzner B; Laurberg S; Christensen P; Grønvold M
    Qual Life Res; 2014 Oct; 23(8):2183-93. PubMed ID: 24676897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
    Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
    PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.